Gapping up
In reaction to strong earnings/guidance:
- N/A.
M&A news:
- THOR +168.5% (to be acquired by Sanofi (SNY) for $68/share in cash)
- XBIT +136.1% (to divest Human antibody Bermekimab targeting IL-1a to Janssen)
- ARQL +100.6% (to be acquired by Merck (MRK) for $20 per share in cash for an approximate total equity value of $2.7 billion)
- RRTS +10.9% (announces the sale of its Flatbed business unit, for $30 mlnin cash)
Other news:
- FATE +25.1% (reports clinical data from Landmark Phase 1 studies; No dose-limiting toxicities or FT500-related SAEs reported in first 12 patients; also presents new in vivo preclinical data for FT596 -- company plans to initiate enrollment of first-in-human clinical trial of FT596 in rarly 2020)
- OBSV +22.1% (reports positive Phase 3 trial results from PRIMROSE 2 trial of linzagolix)
- TGTX +22.1% (presents triple therapy data from Phase I/II study of ublituximab in combination with umbralisib and venetoclax)
- PCG +21% (reaches agreement to resolve wildfires from 2017 and 2018)
- CRTX +14% (reports new data revealing link between bacterial pathogen and genetic risk for Alzheimer's Disease)
- AGIO +12.4% (announces that clinical proof-of-concept has been established based on preliminary analysis of Phase 2 trial of mitapivat in patients with non-transfusion-dependent thalassemia)
- DTIL +9.4% (announces updated interim clinical data from the ongoing Phase 1 trial of its lead investigational off-the-shelf (allogeneic) chimeric antigen receptor (CAR) T cell therapy candidate, PBCAR0191)
- RCKT +7.3% (presents 'encouraging' preliminary results from its Phase 1 trial of commercial-grade RP-L102 "Process B" for Fanconi Anemia)
- ALEC +6.8% (presents Phase 1 data on AL002)
- SGMO +5.5% (Sangamo Therapeutics and Pfizer (PFE) report updated Phase 1/2 results showing sustained increased Factor VIII activity through 44 weeks )
- KPTI +5.3% (reports new and updated XPOVIO data demonstrating 56% overall response)
- BLUE +5% (Bluebirdbio and Bristol-Myers (BMY) report "positive" top-line results from Ph 2 KarMMa study of ide-cel; met its primary endpoint and key secondary endpoint) APTO +3.9% (reports early clinical observations with CG-806 and APTO-253)
- CGC +3.3% (names David Klein CEO effective January 14)
- AM +2.9% (to repurchase $100 mln of shares from Antero Resources)
- CSIQ +2.8% (authorizes $150 mln share repurchase program )
- BMY +2.3% (presents data from multiple studies evaluating lisocabtagene maraleucel at ASH)
- MNK +2.1% (presents data on a novel predictive model to identify infants at risk for infantile spasms)
- SESN +1.7% (initiated the submission of its BLA for Vicinium for the treatment of BCG-unresponsive non-muscle invasive bladder cancer under Rolling Review to the FDA
- MBIO +1.3% (highlights presentation of updated Phase 1/2 clinical data for MB-107 lentiviral gene therapy for X-linked severe combined immunodeficiency)
Analyst comments:
- QRVO +3.4% (upgraded to Buy (from Underperform) at BofA/Merrill)
- SWKS +2.2% (upgraded to Buy (from Underpeform) at BofA/Merrill)
- NUE +1.4% (upgraded to Buy at Longbow)
- STLD +1.1% (upgraded to Buy at Longbow)